Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. (Q47785375)

5 February 2018

title

Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. (English)

1 reference

5 February 2018

1 reference

1 reference

Weiss L

1

1 reference

5 February 2018

Reich S

series ordinal

2

1 reference

5 February 2018

Mandelboim O

series ordinal

3

1 reference

5 February 2018

Slavin S

series ordinal

4

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 June 2004

1 reference

5 February 2018

Bone Marrow Transplantation

published in

1 reference

5 February 2018

volume

33

1 reference

5 February 2018

issue

11

1 reference

5 February 2018

page(s)

1137-1141

1 reference

5 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704475

exact match

0 references

cites work

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Spontaneous murine B-cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Human natural killer cells: their origin, receptors and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

7 January 2021

Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

7 January 2021

Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

7 January 2021

Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704475

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704475

1 reference

5 February 2018

Dimensions Publication ID

0 references

1 reference

5 February 2018